Natera asserts three new oncology patents against ArcherDX (PRNewswire)
"Natera, Inc...asserted three recently issued oncology patents against ArcherDX in its ongoing patent infringement action filed in the U.S. District Court of Delaware....The United States Patent and Trademark Office recently awarded Natera patents 10,557,172; 10,590,482; and 10,597,708, which cover methods for amplifying and sequencing nucleic acids. Natera's complaint alleges that ArcherDX infringes these patents by selling, manufacturing, and/or using various oncology products, including those in the personalized liquid biopsy space."